References
- Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-9
- Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med 2001;344:1773-9
- Evatt BL. Demographics of hemophilia in developing countries. Sem Thromb Hemost 2005;31:489-94
- Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008;14(4 Suppl):3-9
- Rodriguez-Merchan EC. Management of musculoskeletal complications of hemophilia. Sem Thromb Hemost 2003;29:87-96
- Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004;10:147-57
- Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003;9(1 Suppl):57-64
- Zhou ZY, Wu J, Baker J, Curtis R, et al. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011;17:729-36
- Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
- Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011;72:553-62
- Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Sem Thromb Hemost 2000;26:179-88
- Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003;101:4783-8
- Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35
- Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004;127:379-91
- Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63
- Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia 2012;18:332-8
- Globe DR, Cunningham WE, Andersen R, et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003;9:325-31
- Globe DR, Curtis RG, Koerper MA, et al. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(1 Suppl):63-70